Temozolomide represents 38.6% of the product type category and individual pharmacies account for 50.0% of end users demand in 2026. The brain tumor treatment market is estimated at USD 3.8 billion in 2026, is projected to reach USD 7.6 billion by 2036 and is forecast to post a 7.2% CAGR between 2026 and 2036.